Select Page
Responsive Centered YouTube Video
Discussion on the correlation between autoimmunity and COVID-19, aiming to merge clinical practice with research
  • Dr. Shankara Chetty is a family physician in South Africa with a wide range of patients. 1:52

  • Dr. Chetty has successfully managed over 4,000 COVID-19 patients without any deaths, hospitalizations, or need for oxygen. 3:26

  • Global response to Dr. Chetty’s perspective on COVID-19 treatment has been positive, with interest from physicians worldwide. 4:09

  • Dr. Chetty is collaborating with doctors internationally to influence treatment protocols and public health perspectives. 5:31

  • Discussion on autoimmunity in COVID-19, exploring the concept of a hypersensitivity response. 6:12

Understanding the impact of serum ACE-2 in COVID-19 severity and demographics
  • Viral-mediated autoimmune diseases are not uncommon and can trigger autoimmune responses. 6:52

  • Serum ACE-2, when floating freely in serum, may play a significant role in COVID-19 severity. 9:27

  • Demographics of severely affected COVID-19 patients align with characteristics linked to serum ACE-2 levels. 10:12

  • Male sex, ancestry, BMI, diabetes, age, and blood pressure are factors associated with serum ACE-2 levels. 10:41

  • Asian descent and male patients seem to be more affected by COVID-19, possibly due to serum ACE-2 levels. 11:02

  • Virus binding to serum ACE-2 may contribute to the severity of COVID-19 cases. 11:22

Insights on autoimmune response, antibody production, and symptom progression in COVID-19
  • ACE-2 binds efficiently to SARS-COV, leading to autoimmune response. 11:46

  • Primary therapy for COVID-19 involves the use of steroids. 12:11

  • Antibody production critical around the eighth day of infection. 12:50

  • Asymptomatic stage precedes flu-like symptoms in COVID-19 patients. 13:08

  • Interferon production crucial for the body’s defense against the virus. 13:44

  • Clinical recovery often noted on day six or seven, followed by deterioration on the eighth day. 14:27

  • Fatigue commonly experienced on the eighth day, progressing to dyspnoea if unchecked. 16:15

Insights on COVID-19 symptoms progression and immune response triggers
  • Patients may experience fatigue, body aches, and odd temperature spikes on the eighth day. 16:36

  • Shortness of breath may not be the initial symptom, with variable onset times post eighth day. 17:25

  • CRP blood test revealed critical illness despite only experiencing fatigue as a symptom. 18:10

  • Antihistamines and Montelukast showed benefits due to mast cell degranulation and mediators release. 21:45

The use of antihistamines in early COVID-19 treatment and its impact on patient reactions
  • Antihistamines were used early on for symptomatic treatment in COVID-19 patients. 22:03

  • Antihistamines were primarily used to prevent the spread of the virus into the lungs. 22:28

  • Severe allergic reactions on the eighth day were managed with stronger antihistamines. 23:06

  • Elevated serum ACE-2 levels may indicate a risk for severe cytokine storm. 23:31

  • Prior exposure to coronaviruses may lead to mucosal immunity and early interferon response. 24:14

  • Antihistamines early on could potentially mask symptoms critical for detecting reactions on the eighth day. 24:36

  • Education of patients helped in recognizing changes despite the use of antihistamines. 25:18

  • Starting antihistamines early did not stop reactions but may have lessened symptoms. 25:40

  • No major risks associated with starting antihistamines early in COVID-19 illness. 26:37

Insights on COVID-19 clinical practice and symptom monitoring for early intervention
  • Symptoms should be closely monitored, especially on the eighth day of illness. 27:01

  • Patients need to be educated on recognizing changes in symptoms and seeking timely medical attention. 27:38

  • Importance of gauging onset of symptoms and distinguishing from normal health variations. 28:06

  • Advice to mark the eighth day after symptom onset for potential deterioration and intervention. 29:04

  • Observation that COVID-19 tends to resolve by the sixth or seventh day, with eighth day being crucial for intervention. 29:25

  • Significance of eighth day symptoms in determining the course of illness and need for aggressive intervention. 30:06

  • Experience with patient cases showing deterioration specifically on the eighth day of illness. 30:50

  • Caution against early use of ivermectin without clear understanding of its impact on COVID-19 pathophysiology. 31:36

Insights on using ivermectin and immunomodulation in COVID-19 treatment
  • Ivermectin did not impact reactions in COVID-19 patients on the eighth day. 31:59

  • Ivermectin can clear pulmonary eosinophilia and benefit patients with dyspnea. 32:45

  • Research suggests ivermectin may interfere with virus evading interferon response. 34:22

  • Immunomodulation with drugs like Azathioprine could show benefits in COVID-19 treatment. 36:42

Optimizing steroid dosage critical for COVID-19 recovery; prednisone more effective than dexamethasone
  • Steroid dose critical for outcomes; 50mg effective in first wave, 80mg in second wave. 37:24

  • Quickly adjust steroid dose for non-responsive patients; higher doses may be necessary. 38:51

  • Prednisone more effective than dexamethasone for COVID-19 treatment. 41:21

  • High doses of steroids may be necessary for clinical recovery despite concerns. 41:56

Optimizing steroid use in COVID-19 treatment to ensure effectiveness and safety
  • High doses of steroids may be necessary for severe reactions in diabetic patients. 42:15

  • Proper monitoring and adjustment of insulin is crucial when using steroids in diabetic patients. 42:33

  • Steroids should not be avoided due to fear of side effects like black fungus, which is rare. 44:28

  • Clinicians may be hesitant to use high doses of steroids, but appropriate dosing is essential for effective treatment. 45:11

  • In cases of severe pulmonary hypersensitivity, high doses of steroids up to 500mg/day may be necessary. 46:21

  • Appropriate dosing and duration of steroid use are key to stopping the reaction effectively and avoiding prolonged use. 46:41

Insights on immune response, steroid use, and blood parameters in COVID-19 patients
  • Steroids aim to prevent intubation or ventilation to manage severe COVID-19 cases. 47:00

  • Failure to control immune response can lead to lung vasculitis, causing severe damage. 47:54

  • Severe lung vasculitis can result in blocked blood vessels, leading to organ damage. 49:17

  • Histamine, CRP, and interleukin levels can serve as indicators of immune response progression in COVID-19 patients. 51:12

  • D-dimer levels may also be informative in assessing the severity of the immune response. 52:09

  • CRP and interleukin-6 levels spike significantly post day eight, indicating a severe reaction. 52:09

Insights on managing COVID-19 patients, focusing on immune response, clotting issues, and long covid potential triggers
  • D-dimers and clotting profile tended to rise after the 8th day. 52:30

  • CRP and interleukins were good markers for patient response. 52:51

  • Anticoagulation became important for patients with clotting issues. 53:36

  • Early intervention crucial to prevent hospitalization and escalation of treatment. 54:00

  • Antivirals may not be effective in later stages of COVID-19 infection. 54:40

  • Long covid potentially linked to immune changes triggered by diet. 55:29

  • Steroids and antihistamines early on led to recovery in all treated patients. 56:30

  • No cases of long covid observed in patients treated early with the mentioned approach. 56:54

  • Similar approach showed positive results in patients with long covid symptoms. 57:12

Optimal treatment approach for COVID-19 patients to prevent severe outcomes and mortality
  • A combination of aspirin, antihistamines, and Montelukast can lead to clinical recovery within a few days. 57:30

  • Early intervention is crucial at the onset of deterioration, typically around the eighth day. 57:45

  • Long COVID may result from an inappropriate immune response that can be mitigated with timely treatment. 58:08

  • Consider COVID-19 as a self-limiting virus and focus on managing the individual’s immune response. 1:00:10

  • Challenge traditional paradigms in managing COVID-19 to improve outcomes and reduce mortality rates. 1:00:33

  • Re-evaluate the approach to COVID-19 treatment to prevent fear-driven practices and encourage early, proactive care. 1:00:56

  • Mortality in COVID-19 is often due to delayed treatment and isolation without proper intervention. 1:01:23

  • Utilize high-dose steroids without hesitation to control the inflammatory response. 1:02:05

  • Administer antihistamines to suppress additional immune responses, particularly from mast cells. 1:02:28

Importance of recognizing symptoms on the eighth day in COVID-19 treatment
  • Starting treatment on the eighth day is crucial and every day lost is significant. 1:02:52

  • Interrogating patients on the eighth day is essential to identify symptoms. 1:03:15

  • Education about the importance of the eighth day is vital for the community. 1:03:33

  • Continued discussions and collaborations with Dr. Shankara Chetty are expected in the future. 1:03:47

  • Expressing gratitude and signing off the conversation. 1:05:07